KevinMD.com: Social media’s leading physician voice
The KevinMD newsletterReal physician voices, twice a weekFree, and one click to unsubscribe.
Subscribe free →

Will Januvia take out Byetta?

OnThePharm thinks so. The GLP-1 based therapies are an exciting new class of diabetes medications. So far, Byetta has worked well for my patients – the jury is still out with Januvia. Merck certainly hopes that Januvia will rescue them.

Share this articleLinkedInFacebookXEmail

Real physician voices, twice a week

Free, and one click to unsubscribe.

No spam. We never share your email.